Roanna Ruiz has given his Buy rating due to a combination of factors related to the promising progress of Cytokinetics' clinical programs and strategic regulatory engagements. The analyst highlights the clear timeline for the regulatory submissions of aficamten in obstructive hypertrophic cardiomyopathy (oHCM), with the New Drug Application (NDA) expected in the third quarter of 2024 and the Marketing Authorization Application (MAA) in the fourth quarter. Ruiz notes the encouraging sign that no additional studies have been requested by regulatory agencies, hinting at a potentially smoother path to approval. The management's proactive approach to communication and publication of the SEQUOIA trial results further solidifies this view. Additionally, Roanna Ruiz's confidence is bolstered by Cytokinetics' ongoing preparations for the commercial launch of aficamten in the U.S. and their strategic entry into the European market, starting with Germany.